To date, most biomarker studies on AD have focused on the use of cerebrospinal fluid (CSF) and blood plasma levels of β-amyloid, tau, and phosphorylated tau in relation to clinical symptoms and survival as diagnostic specimens [10,11,12,13,14,15]. Here, MAPT is linked to Alzheimer disease.